AMED indicates Allied and Complementary Medicine Database; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-analyses.
Weights are from random-effects analysis. Forty-five studies were included.
Weights are from random-effects analysis. Twenty-one studies were included.
eTable 1. Search Sequence for Ovid Medline Which Was Subsequently Adapted for Other Databases
eFigure 1. A Map Showing the Geographical Spread of the Countries From Which Data Were Collected
eFigure 2. Funnel Plot of Incidence Rates of Frailty Among Community-Dwelling Older Adults
eFigure 3. Forest Plot of Incidence Rates of Frailty Among Community-Dwelling Older Adults When Factoring in Progression to Deaths in Studies With Death Data
eFigure 4. Forest Plot of Incidence Rates of Frailty Among Community-Dwelling Older Adults When Limiting to Survivors in Studies With Death Data
eFigure 5. Funnel Plot of Incidence Rates of Pre-frailty Among Community-Dwelling Older Adults
eFigure 6. Forest Plot of Incidence Rates of Pre-frailty Among Community-Dwelling Older Adults When Factoring in Progression to Deaths in Studies With Death Data
eFigure 7. Forest Plot of Incidence Rates of Pre-frailty Among Community-Dwelling Older Adults When Limiting to Survivors in Studies With Death Data
eTable 2. Estimates From Leave-One-Out Sensitivity Analyses for the Incidence of Frailty
eTable 3. Estimates of Leave-One-Out Sensitivity Analyses for the Incidence of Pre-frailty
Customize your JAMA Network experience by selecting one or more topics from the list below.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ofori-Asenso R, Chin KL, Mazidi M, et al. Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019;2(8):e198398. doi:10.1001/jamanetworkopen.2019.8398
What is the incidence of frailty and prefrailty among community-dwelling adults 60 years or older?
In this systematic review and meta-analysis involving data from more than 120 000 older adults from 28 countries, the incidence of frailty and prefrailty was estimated as 43.4 and 150.6 new cases per 1000 person-years, respectively. The frailty and prefrailty incidence rates varied by sex, diagnostic criteria, and country income level.
Results of this study suggest that the risk of developing frailty and prefrailty is high among community-living older adults; as such, appropriate interventions are needed.
Frailty is a common geriatric syndrome of significant public health importance, yet there is limited understanding of the risk of frailty development at a population level.
To estimate the global incidence of frailty and prefrailty among community-dwelling adults 60 years or older.
MEDLINE, Embase, PsycINFO, Web of Science, CINAHL Plus, and AMED (Allied and Complementary Medicine Database) were searched from inception to January 2019 without language restrictions using combinations of the keywords frailty, older adults, and incidence. The reference lists of eligible studies were hand searched.
In the systematic review, 2 authors undertook the search, article screening, and study selection. Cohort studies that reported or had sufficient data to compute incidence of frailty or prefrailty among community-dwelling adults 60 years or older at baseline were eligible.
Data Extraction and Synthesis
The methodological quality of included studies was assessed using The Joanna Briggs Institute’s Critical Appraisal Checklist for Prevalence and Incidence Studies. Meta-analysis was conducted using a random-effects (DerSimonian and Laird) model.
Main Outcomes and Measures
Incidence of frailty (defined as new cases of frailty among robust or prefrail individuals) and incidence of prefrailty (defined as new cases of prefrailty among robust individuals), both over a specified duration.
Of 15 176 retrieved references, 46 observational studies involving 120 805 nonfrail (robust or prefrail) participants from 28 countries were included in this systematic review. Among the nonfrail individuals who survived a median follow-up of 3.0 (range, 1.0-11.7) years, 13.6% (13 678 of 100 313) became frail, with the pooled incidence rate being 43.4 (95% CI, 37.3-50.4; I2 = 98.5%) cases per 1000 person-years. The incidence of frailty was significantly higher in prefrail individuals than robust individuals (pooled incidence rates, 62.7 [95% CI, 49.2-79.8; I2 = 97.8%] vs 12.0 [95% CI, 8.2-17.5; I2 = 94.9%] cases per 1000 person-years, respectively; P for difference < .001). Among robust individuals in 21 studies who survived a median follow-up of 2.5 (range, 1.0-10.0) years, 30.9% (9974 of 32 268) became prefrail, with the pooled incidence rate being 150.6 (95% CI, 123.3-184.1; I2 = 98.9%) cases per 1000 person-years. The frailty and prefrailty incidence rates were significantly higher in women than men (frailty: 44.8 [95% CI, 36.7-61.3; I2 = 97.9%] vs 24.3 [95% CI, 19.6-30.1; I2 = 8.94%] cases per 1000 person-years; prefrailty: 173.2 [95% CI, 87.9-341.2; I2 = 99.1%] vs 129.0 [95% CI, 73.8-225.0; I2 = 98.5%] cases per 1000 person-years). The incidence rates varied by diagnostic criteria and country income level. The frailty and prefrailty incidence rates were significantly reduced when accounting for the risk of death.
Conclusions and Relevance
Results of this study suggest that community-dwelling older adults are prone to developing frailty. Increased awareness of the factors that confer high risk of frailty in this population subgroup is vital to inform the design of interventions to prevent frailty and to minimize its consequences.
The increasing average life expectancy has contributed to aging of the world’s population.1 By 2050, approximately 21.3% of the global population will be 60 years or older,2 up from 9.2% in 1990. Frailty, a clinical syndrome characterized by marked vulnerability due to decline in reserve and function across multiple physiologic systems, is common among older people.3,4 Frailty manifests as the inability to tolerate stressful events and has been associated with adverse outcomes, such as falls,5 delirium,6 institutionalization,7 incident disability,8 and mortality.9 Frailty is also an independent risk factor for poor outcomes after surgery (eg, prolonged hospitalizations, increased susceptibility to deconditioning, and faster functional decline)10 and is associated with higher health care use11 and corresponding costs.12 There is a growing interest among stakeholders in aged care to better understand the patterns and determinants of frailty.13
Frailty is difficult to diagnose, particularly within primary care settings, due to its coexistence with other age-related conditions and as a result of the lack of a universally accepted clinical definition.14,15 There is also debate about frailty screening, especially in relation to screening eligibility, as well as where and when it should be done.16
Frailty phenotype and deficit accumulation are 2 main approaches to frailty assessment.4 Using the phenotype approach, Fried et al17 defined frailty as a predominantly physical condition requiring the presence of 3 or more of the following 5 components: weight loss, exhaustion, weakness, slowness, and low physical activity. However, Rockwood et al18 characterized frailty as an accumulation of deficits (symptoms, signs, functional impairment, and laboratory abnormalities) and stipulated that more deficits confer greater risk. These 2 frailty conceptualizations have been extensively validated and are widely used. Beyond these conceptualizations of frailty, several other definitions are present in the literature.19 Many definitions consider frailty to be a dynamic process with an identifiable intermediate stage, usually referred to as prefrailty.20
Since 2000, frailty-related research has increased exponentially.15 Nonetheless, the epidemiological evidence on frailty is dominated by a focus on prevalence. Incidence remains poorly understood. Although Galluzzo et al21 previously performed a systematic review on frailty incidence, their analysis focused on European ADVANTAGE Joint Action countries and included 6 studies, with no meta-analysis performed. With a growing worldwide interest in healthy aging,22 improved understanding of the incidence of frailty may help deepen the discourse around the maintenance of functional ability in old age. Therefore, we conducted a systematic review and meta-analysis to summarize the available global epidemiological data on the incidence of frailty and prefrailty among community-dwelling adults 60 years or older.
This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses23 (PRISMA) and Meta-analysis of Observational Studies in Epidemiology24 (MOOSE) reporting guidelines. The study protocol is registered at PROSPERO (CRD42019121302).25
Two of us (R.O-A. and K.L.C) independently determined study eligibility, and any disagreements were resolved via consensus involving a third reviewer (D. Liew). The inclusion criteria were cohort studies that reported or had sufficient data to compute incidence of frailty or prefrailty among community-dwelling adults 60 years or older at baseline. Frailty status was considered categorically as robust, prefrail, or frail.26 Frailty could have been diagnosed by any method, but studies needed to specify their definition. For the Fried phenotype, individuals are often classified as robust, prefrail, or frail if 0, 1 to 2, or 3 or more of the criteria (ie, weight loss, exhaustion, weakness, slowness, and low physical activity) are met, respectively.17 For the deficit accumulation approach, the definitions of robust, prefrail, and frail were as specified by study authors, as has been done previously.27,28 Incidence of frailty was defined as new cases of frailty among robust or prefrail individuals, and incidence of prefrailty was defined as new cases of prefrailty among robust individuals, both over a specified duration. When multiple studies used the same cohort, the study with the most complete data on the largest number of participants was selected.
Exclusion criteria included studies focusing on institutionalized or hospitalized adults, residents of nursing homes (because these populations are often predominantly frail),29 or populations selected on the basis of an index disease. Studies reporting the mean frailty scores but without data on incidence were excluded, as were randomized clinical trials. Studies of individuals across the life span were excluded unless data were specifically available for those 60 years or older at baseline.
In the systematic review, 2 of us (R.O-A. and K.L.C.) undertook the search, article screening, and study selection. MEDLINE, Embase, PsycINFO, Web of Science, CINAHL Plus, and AMED (Allied and Complementary Medicine Database) were searched from inception to January 2019 without language restrictions using combinations of the keywords frailty, older adults, and incidence. eTable 1 in the Supplement lists the search terms and strategy for MEDLINE (via Ovid), which were adapted for other databases. The reference lists of eligible studies were hand searched. Conference abstracts, editorials, and meeting reports were excluded.
Two of us (R.O-A. and K.L.C.) evaluated each included study for methodological quality using The Joanna Briggs Institute’s Critical Appraisal Checklist for Prevalence and Incidence Studies.30 This checklist consists of 9 criteria, and studies were ineligible if fewer than 5 of the criteria were achieved.
The following information was collected from individual articles: study details (authors, year of publication, country, and study name), participant characteristics (sample size and percentage of women), frailty measurement method, duration of follow-up, and incidence data. Sex-stratified or age-stratified incidence data were collected, where available. Authors were contacted for additional data or clarification, when required.
For each study, we recorded or calculated incidence rates of frailty or prefrailty per 1000 person-years based on the event rates and the mean duration of follow-up.27,31-33 Exact methods according to the Poisson distribution were adopted to calculate 95% CIs for incidence rates.34 There were 2 kinds of studies, including (1) those that used a 100% survivor cohort (ie, assessed frailty status at 2 time points, excluding persons who died in-between) and (2) those that accounted for people in the cohort who died without developing frailty. Therefore, to improve the comparability of these 2 types of studies, as well as to minimize the consequences of survivorship bias,35 we recalculated the incidence rate in the latter studies (ie, studies that reported transition to deaths) by restricting the sample to the surviving cohort with frailty data.27,36
A random-effects (DerSimonian and Laird) meta-analysis was conducted using the log-transformed incidence rates and corresponding 95% CIs. The random-effects model was selected a priori due to the anticipated heterogeneity of the included studies. Statistical evidence of between-study heterogeneity was examined using the Cochran Q test and the I2 statistic.37I2 values of 25%, 50%, and 75% were considered to be low, moderate, and high degrees of heterogeneity, respectively.37 The robustness of pooled estimates were assessed via leave-1-out sensitivity analyses. A study was considered to be influential if the pooled estimate without it was not within the 95% CIs of the overall pooled estimate. Sex-specific incidence data were pooled, as were the incidence rates by assessment method. To examine the extent to which the pooled incidence rates were explained by these factors, we also performed random-effects meta-regression using the following variables: measurement method (physical phenotype vs other), country income level (lower-income and middle-income country [LMIC] vs high-income country [HIC]), study region (North America, Europe, Asia, or other), person-years of follow-up (per unit increase), whether the study enrolled only elderly people 70 years or older (no vs yes), study population (mix, female only, or male only), and publication years (2009 or earlier, 2010 to 2014, or 2015 to 2019). The HICs were defined as any country with a gross national income per capita in 2017 of US $12 056 or more.38 Differences between subgroups were compared via a χ2 test. Publication bias was assessed via visual inspection of funnel plots, and statistical assessment was evaluated using the Egger test.39
To provide context of the burden of frailty, data on the proportion of older adults who were nonfrail were pooled using the respective study baseline data, if reported. The meta-analysis was performed using the Freeman-Tukey double arcsine transformed proportions to stabilize the variance.40
All analyses were performed using statistical software (Stata, version 15.0/IC; StataCorp LP). Two-tailed P < .05 was considered statistically significant.
Of 15 176 retrieved citations, 142 articles were selected for full-text assessment (Figure 1). After full-text evaluation, 42 studies met the eligibility criteria. Four additional studies were retrieved by reference screening, resulting in a total of 46 studies (involving 48 cohorts) included in the systematic review. No study was excluded on the basis of The Joanna Briggs Institute methodological review.30
The characteristics of the 46 included studies are summarized in Table 1. The studies involved 120 805 nonfrail (robust or prefrail) older adults from 28 countries. Nine studies were from Asia, 14 from North America, 2 from South America, 15 from Europe, and 4 from Australia, and 2 were cross-regional studies. eFigure 1 in the Supplement shows the geographical spread of the countries where data were collected. The median sample size across studies was 1054 (range, 44-28 181), and the median follow-up was 3.0 (range, 1.0-11.7) years. In 30 studies involving 101 259 participants, 73.3% were women. Frailty was assessed using the original or modified versions of the Fried criteria in 39 studies, 4 studies used the Frailty Index, and 1 study used both the Frailty Index and the Fried criteria, whereas 2 studies used other criteria. Among the studies using the deficit accumulation approach, the number of deficits used ranged from 20 to 44.
In 31 studies, data on baseline proportion of older adults without frailty were available. In these studies, involving 118 411 individuals at baseline, the pooled proportion without frailty was 82.8% (95% CI, 75.8%-88.8%; I2 = 99.8%). The pooled proportion that was nonfrail was 86.5% (95% CI, 78.9%-92.7%; I2 = 99.8%) across studies that used the Fried criteria and 58.9% (95% CI, 44.2%-72.8%; I2 = 99.6%) across studies that used other criteria (P for difference < .001).
To estimate the global incidence of frailty, data were included from 46 studies.41-81,83-86 Among people without frailty at baseline who survived a median follow-up of 3.0 (range, 1.0-11.7) years, 13.6% (13 678 of 100 313) became frail. The pooled incidence rate of frailty was 43.4 (95% CI, 37.3-50.4; I2 = 98.5%) cases per 1000 person-years (Figure 2). There was no evidence of publication bias as determined by funnel plot visualization (eFigure 2 in the Supplement) or via the Egger test (P = .48). A leave-1-out sensitivity analysis did not show a dominance of any single study (eTable 2 in the Supplement).
The pooled frailty incidence rate was 40.0 (95% CI, 34.5-48.5; I2 = 98.2%) cases per 1000 person-years when using the Fried phenotype. The pooled frailty incidence rate was 71.3 (95% CI, 56.9-89.3; I2 = 94.0%) cases per 1000 person-years when using other criteria (P for difference = .003).
Among 20 studies that reported transitions to death, the proportion of nonfrail people who died over a median follow-up of 4.5 years was 12.9% (5989 of 46 358). When factoring in the risk of death, the pooled incidence rate of frailty was 35.9 (95% CI, 28.0-46.1; I2 = 98.7%) cases per 1000 person-years (eFigure 3 in the Supplement). Restricting the analyses to those who survived in these 19 studies resulted in a pooled frailty incidence rate of 44.1 (95% CI, 34.0-57.2; I2 = 98.8%) cases per 1000 person-years (eFigure 4 in the Supplement).
Twenty studies reported the incidence of frailty among 19 613 people who were prefrail and 17 523 people who were robust at baseline and who survived over a median follow-up of 3.0 years. During the follow-up, 4.6% (807 of 17 523) of individuals who were robust and 18.5% (3628 of 19 613) of individuals who were prefrail developed frailty. The pooled frailty incidence rates among the robust and prefrail individuals were 12.0 (95% CI, 8.2-17.5; I2 = 94.9%) and 62.7 (95% CI, 49.2-79.8; I2 = 97.8%) cases per 1000 person-years, respectively, with the difference being statistically significant (P value for difference < .001).
Ten studies directly compared frailty incidence between 11 959 men and 13 870 women who survived a median follow-up of 4.0 years. Among the men and women, 9.2% (1099 of 11 959) and 15.6% (2164 of 13 870), respectively, developed frailty. The pooled incidence rates of frailty in men and women in these studies were 24.3 (95% CI, 19.6-30.1; I2 = 89.4%) and 44.8 (95% CI, 36.7-61.3; I2 = 97.9%) cases per 1000 person-years, respectively, with the difference being statistically significant (P value for difference = .01).
Only 2 studies48,75 reported age-stratified frailty incidence rate, with inconsistent age groups being used. Therefore, data were not pooled, although both studies reported consistent increases in frailty incidence with increasing age.
Twenty-one studies41,42,46,51,53,57,59,60,65-69,71,72,77,79-83 reported data on the global incidence of prefrailty among 32 268 community-dwelling older adults who were robust at baseline and survived a median follow-up of 2.5 (range, 1.0-10.0) years. During the follow-up, 30.9% (9974 of 32 268) became prefrail. The pooled incidence rate of prefrailty was 150.6 (95% CI, 123.3-184.1; I2 = 98.9%) cases per 1000 person-years (Figure 3). There was no evidence of publication bias as determined by visual inspection of funnel plots (eFigure 5 in the Supplement) or by means of the Egger test. A leave-1-out sensitivity analysis did not alter the results (eTable 3 in the Supplement).
The pooled incidence rate of prefrailty was 150.9 (95% CI, 120.2-182.6; I2 = 98.8%) cases per 1000 person-years when using the Fried phenotype. The pooled incidence rate of prefrailty was 140.4 (95% CI, 97.2-202.9; I2 = 93.4%) cases per 1000 person-years when using other criteria (P for difference = .52).
Among 13 studies that reported transitions to death, the proportion of robust people who died over a median follow-up of 4.0 years was 7.8% (1253 of 16 134). When factoring in the risk of death, the pooled incidence rate of prefrailty was 110.6 (95% CI, 84.8-144.2; I2 = 98.9%) cases per 1000 person-years (eFigure 6 in the Supplement). Restricting the analyses to those who survived in these 13 studies resulted in a pooled prefrailty incidence rate of 122.7 (95% CI, 95.7-157.5; I2 = 98.7%) cases per 1000 person-years (eFigure 7 in the Supplement).
Four studies directly compared incidence of prefrailty among 4003 men and 3655 women who survived a median follow-up of 4.2 years. In all, 32.6% (1305 of 4003) of the men and 40.1% (1465 of 3655) of the women became prefrail, at a pooled incidence rate of 129.0 (95% CI, 73.8-225.0; I2 = 98.5%) and 173.2 (95% CI, 87.9-341.2; I2 = 99.1%) cases per 1000 person-years, respectively (P for difference = .12). No study reported age-stratified prefrailty incidence data.
In the multivariable random-effects meta-regression, measuring frailty as a physical phenotype was associated with higher incidence than using other methods (adjusted odds ratio [aOR], 1.48; 95% CI, 1.02-2.15), although no statistically significant difference was observed for prefrailty incidence (Table 2). Study region was not significantly associated with frailty and prefrailty incidence, but HICs were associated with a lower incidence of frailty (aOR, 0.63; 95% CI, 0.42-0.95) and prefrailty (aOR, 0.30; 95% CI, 0.21-0.84) compared with LMICs. Studies published after 2009 were associated with lower frailty incidence. The variables included in the multivariable models collectively explained about 63.9% and 38.1% of the between-study variance for frailty and prefrailty incidence, respectively.
We performed a systematic review and meta-analysis to estimate the incidence of frailty and prefrailty among community-dwelling older adults. Our results indicate the following: (1) frailty and prefrailty incidence rates were approximately 43 and 151 new cases per 1000 person-years, respectively; (2) the incidence of frailty and prefrailty was higher in women than men; and (3) the incidence of frailty and prefrailty varied by frailty measurement method used and by country income level.
Although not necessarily synonymous with aging, frailty is highly prevalent among older people.3,4 Our pooled baseline data suggested that approximately 1 in 6 community-dwelling older people may have frailty. Frailty has been associated with adverse health outcomes, such as falls, disability, and death, as well as increased use of health care resources.8,9,12 Therefore, efforts to reduce the burden of frailty could have substantial public health consequences.
Prevention of frailty requires a sound understanding of the risk factors. For example, it has been demonstrated that individual chronic diseases (eg, cancers, type 2 diabetes,63,66,71 and depression,77,85,87 or their co-occurrence [ie, multimorbidity]) have been shown to increase the risk of frailty.88,89 With an estimated 66% of older people having at least 2 chronic medical conditions,90 effective preventive strategies are paramount to reduce overall disease burden. The rising prevalence of obesity among older adults91,92 needs greater attention because this condition, particularly abdominal obesity, may increase the risk of frailty through the association with proinflammatory processes, insulin resistance, fat infiltration of skeletal muscles, and hormonal alterations.93,94 Many other sociodemographic, physical, biological, lifestyle (eg, smoking), and psychological factors may equally contribute to the development of frailty and thus require tailored solutions in different settings.95-98
We found a higher incidence of frailty and prefrailty in LMICs than HICs in our study, which is consistent with prior observations of significantly higher prevalence of frailty and prefrailty in LMICs compared with HICs.99 Some studies59,87,100 found that high income and educational levels and greater access to and quality of health care confer lower frailty risk, which may partly explain the disparity in frailty incidence between LMICs and HICs, presenting opportunity to prevent or delay the onset of chronic pathologies associated with increased risk of frailty.88,101
Our meta-analysis suggests higher incidence of frailty and prefrailty in women than men. Previous studies have shown consistently higher prevalence rates3,99 and frailty scores102 among women than men across all age groups. The sex differences may be attributable to both biological and socioeconomic factors. Nonetheless, women have been found to better tolerate frailty, as evidenced by lower mortality rates at any frailty level or age, suggesting the existence of a male-female health-survival paradox.102
To date, several interventions incorporating exercise, nutrition, cognitive training, geriatric assessment, hormone therapy, and management and prehabilitation have been evaluated for their effectiveness at delaying or reversing frailty.103-107 Most of these interventions have demonstrated feasibility, with adherence rates of about 70%.103 However, a recent systematic review reported that, among the available primary care interventions to delay or reverse frailty, strength training and protein supplementation ranked highest in terms of relative effectiveness and ease of implementation.108 Conversely, mild-intensity mixed exercises, as well as educational or health promotion activities, typically were in the midzone for both relative effectiveness and ease of implementation, whereas comprehensive geriatric assessments and home visits were ranked mid to low for both relative effectiveness and ease of implementation. In general, interventions targeting behavioral change ranked low in relative effectiveness and at the midzone for ease of implementation.108 However, it needs emphasizing that most interventions have been tested in people who were frail or prefrail.103,108 Our meta-analysis showed that, among people who were robust, there were approximately 12 and 151 new cases of frailty and prefrailty per 1000 person-years, respectively, suggesting that interventions aimed at preventing frailty and prefrailty in robust populations could be important.
The lower pooled incidence when frailty was defined as a physical phenotype compared with when a broad phenotype was used is consistent with prior meta-analyses that have demonstrated higher frailty prevalence when using broad definitions vs the physical phenotype.3,99 Other studies3 have shown considerable variability in the literature regarding the use of the deficit accumulation approach (as also observed in the present study), thus contributing to wide estimates of frailty burden. Therefore, a harmonized definition of frailty may be useful.
Our study had some limitations. There was substantial heterogeneity of the included studies. Nonetheless, heterogeneity is often inevitable in meta-analyses of observational studies, and it does not necessarily invalidate the findings.109 We decided a priori to pool incidence data across studies that met our inclusion criteria. Furthermore, potential sources of heterogeneity were investigated via subgroup and random-effects meta-regression, which showed considerable heterogeneity in incidence rates by frailty measurement method, country income level, and publication years of studies. Meta-analysis of incidence data is also complicated by variable duration of follow-up. We sought to overcome this by estimating person-years on the basis of the median follow-up duration. While this method is considered robust and is widely applied in the literature,27,31-33 a more precise approach would have required the use of the actual data on person-years, which were unavailable in more than 90% of studies. While frailty incidence varies by age, we could not perform age-stratified analysis due to limited data, and we were unable to account for the influence of the mean age of participants in the individual studies in the regression models due to poor reporting. People who develop frailty or prefrailty may regress27,36; however, the present analysis does not incorporate regression rates. Finally, our abstract screening may have missed relevant studies in which frailty was not the main focus, but which contained information on the incidence of frailty (eg, frailty as a covariate).
Overall, the study results reiterate the need for regular screening programs to assess older people’s vulnerability to frailty development so that appropriate interventions can be implemented in a timely manner.16 For example, frailty assessment could be considered as part of routine health screening or could be instituted as a part of the core services delivered to older people within primary health care and general practice settings.41 Because not all older people develop frailty, future studies should examine protective factors against frailty so as to inform preventive strategies. Our data could also inform health care planning and design of preventive strategies. However, the inequality in the availability of frailty data according to geographical locations requires attention because it hampers the opportunity to reliably forecast the future trajectory of the global burden of frailty, which is needed to inform efficient planning and resource allocation, mindful of the growing aging population.21
There is a high risk of frailty among community-dwelling older adults, and we observed that the incidence of frailty varies by sex, region, country income level, and diagnostic criteria used. It is imperative to improve understanding of the factors that confer increased risk of frailty. This will help inform the design of interventions to prevent frailty or minimize its negative consequences on health.
Accepted for Publication: June 13, 2019.
Published: August 2, 2019. doi:10.1001/jamanetworkopen.2019.8398
Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2019 Ofori-Asenso R et al. JAMA Network Open.
Corresponding Author: Danny Liew, MBBS(Hons), FRACP, PhD, School of Public Health and Preventive Medicine, Monash University, 553 St Kilda Rd, Melbourne, Victoria, Australia 3004 (firstname.lastname@example.org).
Author Contributions: Drs Ofori-Asenso and Chin had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Ofori-Asenso, Chin, Liew.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Ofori-Asenso, Liew.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Ofori-Asenso, Chin.
Conflict of Interest Disclosures: Dr Zomer reported receiving grants and/or personal fees from Amgen, AstraZeneca, Pfizer, and Shire. Dr Zullo reported being supported in part by a Brown University Office of the Vice President for Research Seed Funding Award, receiving an Agency for Healthcare Research and Quality award, and receiving grants from Sanofi Pasteur. Dr Bell reported receiving grants from the National Health and Medical Research Council, Dementia Australia Research Foundation, Victorian Government Department of Health and Human Services, and aged care provider organizations. Dr Liew reported receiving grants from Pfizer, AbbVie, AstraZeneca, and CSL-Behring and personal fees and/or other financial support from Bayer and Novartis. No other disclosures were reported.
Additional Contributions: We thank the study authors who provided us with additional data.